New paper about a Gilead drug to combat coronavirus has analysts skittish

New paper about a Gilead drug to combat coronavirus has analysts skittish

A new paper about a Gilead drug to combat coronavirus has some analysts skittish about success

By ED SILVERMAN

COURTESY NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES-ROCKY MOUNTAIN LABORATORIES, NIH

“We continue to see a less than 50/50 possibility that the drug is ultimately proven effective," wrote RBC Capital Markets analysts about a new paper.

READ MORE